Serum activity of prolyl endopeptidase, but not of dipeptidyl peptidase IV, is decreased by immunotherapy with IFN-alpha in high-risk melanoma patients.

Immunotherapy with interferon-alpha (IFN-alpha) induces neuropsychiatric side effects, most notably depression. In hepatitis patients treated with IFN-alpha, severity of depression correlates with a decrease in serum activity of dipeptidyl peptidase IV (DPP-IV, EC 3.4.14.5), a membrane-bound protease involved in the cleavage of cytokines and neuroactive peptides. Abnormal serum activity of the cytosolic peptidase prolyl endopeptidase (PEP, EC 3.4.21.26, postprolyl cleaving enzyme, prolyl oligopeptidase) has been documented in patients with a variety of psychiatric disorders, most consistently in mood disorders. The serum activity of PEP and DPP-IV was measured before and after 4 weeks of high-dose induction treatment with IFN-alpha in 18 patients with high-risk melanoma. In this exploratory study, we show a clear decrease in the serum activity of PEP after 4 weeks of treatment with IFN-alpha. This decrease was not related to changes in hematologic parameters. In contrast, serum activity of DPP-IV did not change. Further studies focusing on a possible role of PEP in the pathophysiology of IFN-alpha-induced depression are warranted.

[1]  A. Eggermont,et al.  Neuropsychiatric side effects of interferon‐alfa therapy , 2003, Pharmacy World and Science.

[2]  G. Glenner,et al.  A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-β-naphthylamide , 2004, Histochemie.

[3]  A. Eggermont,et al.  Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients , 2003, Psychiatry Research.

[4]  C. Durinx,et al.  Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV , 2003, Critical reviews in clinical laboratory sciences.

[5]  M. Maes,et al.  Mechanisms of interferon-alpha-induced depressive symptoms , 2002, Acta Neuropsychiatrica.

[6]  A. Harwood,et al.  A common mechanism of action for three mood-stabilizing drugs , 2002, Nature.

[7]  H. Meltzer,et al.  Increased Depressive Ratings in Patients With Hepatitis C Receiving Interferon-α–Based Immunotherapy Are Related to Interferon-α–Induced Changes in the Serotonergic System , 2002 .

[8]  R. Dantzer,et al.  Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy , 2002, Molecular Psychiatry.

[9]  D. Fekkes,et al.  Effect of electroconvulsive therapy on biopterin and large neutral amino acids in severe, medication-resistant depression , 2001, Psychiatry Research.

[10]  H. Meltzer,et al.  Treatment with interferon-alpha (IFNα) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFNα-induced depressive and anxiety symptoms and immune activation , 2001, Molecular Psychiatry.

[11]  B. Klapp,et al.  Eating disorders: a role for dipeptidyl peptidase IV in nutritional control. , 2001, Nutrition.

[12]  H. Neels,et al.  Reference Values for Plasma Dipeptidyl Peptidase IV Activity and Their Association with Other Laboratory Parameters , 2001, Clinical chemistry and laboratory medicine.

[13]  R. Dantzer,et al.  Lowered Serum Dipeptidyl Peptidase IV Activity is Associated with Depressive Symptoms and Cytokine Production in Cancer Patients Receiving Interleukin-2-Based Immunotherapy , 2001, Neuropsychopharmacology.

[14]  M. Maj,et al.  Lower serum activity of prolyl endopeptidase in anorexia and bulimia nervosa , 2001, Psychoneuroendocrinology.

[15]  R. Dantzer,et al.  The vagus nerve mediates behavioural depression, but not fever, in response to peripheral immune signals; a functional anatomical analysis , 2000, The European journal of neuroscience.

[16]  E. Bosmans,et al.  Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. , 2000, European journal of biochemistry.

[17]  B. Redman,et al.  Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Willenbring,et al.  Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. , 2000, The American journal of psychiatry.

[19]  D. Remick,et al.  Cytokines and the brain: implications for clinical psychiatry. , 2000, The American journal of psychiatry.

[20]  M. Maj,et al.  Lowered Serum dipeptidyl peptidase IV activity in patients with anorexia and bulimia nervosa , 2000, European Archives of Psychiatry and Clinical Neuroscience.

[21]  M. Eames,et al.  Loss of a prolyl oligopeptidase confers resistance to lithium by elevation of inositol (1,4,5) trisphosphate , 1999, The EMBO journal.

[22]  R. Pioli,et al.  Higher serum prolyl endopeptidase activity in patients with post-traumatic stress disorder. , 1999, Journal of affective disorders.

[23]  S. Bonaccorso,et al.  Lower serum activity of prolyl endopeptidase in fibromyalgia is related to severity of depressive symptoms and pressure hyperalgesia , 1998, Psychological Medicine.

[24]  M. Gompels,et al.  Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients. , 1998, Clinical chemistry.

[25]  H. Neels,et al.  Lower serum dipeptidyl peptidase IV activity in treatment resistant major depression: Relationships with immune-inflammatory markers , 1997, Psychoneuroendocrinology.

[26]  H. Meltzer,et al.  Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs , 1996, Acta psychiatrica Scandinavica.

[27]  J. Calabrese,et al.  Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs , 1995, Psychiatry Research.

[28]  A. van Dalen,et al.  Validation of the determination of amino acids in plasma by high-performance liquid chromatography using automated pre-column derivatization with o-phthaldialdehyde. , 1995, Journal of chromatography. B, Biomedical applications.

[29]  B. Palumbo,et al.  Interferon-α-Induced Biologic Modifications in Patients with Chronic Myelogenous Leukemia , 1994 .

[30]  H. Meltzer,et al.  Lower serum prolyl endopeptidase enzyme activity in major depression: Further evidence that peptidases play a role in the pathophysiology of depression , 1994, Biological Psychiatry.

[31]  C. Ferrario,et al.  A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. , 1993, Life sciences.

[32]  G. Vanhoof,et al.  Decreased serum dipeptidyl peptidase IV activity in major depression , 1991, Biological Psychiatry.

[33]  P. Ward,et al.  Kinin and angiotensin metabolism by purified renal post-proline cleaving enzyme. , 1987, Biochemical pharmacology.

[34]  I. Nagaoka,et al.  Possible involvement of aminopeptidase, an ecto-enzyme, in the inactivation of bradykinin by intact neutrophils. , 1985, Biochimica et biophysica acta.

[35]  P. López-Jaramillo,et al.  Effect of gonadal steroids on hypothalamus and anterior pituitary endo-oligopeptidase B (proline-endopeptidase) activity in castrated female rats , 1984, Peptides.

[36]  P. Emson,et al.  Degradation of neurotensin by rabbit brain endo-oligopeptidase A and endo-oligopeptidase B (proline-endopeptidase). , 1983, Biochemical and biophysical research communications.